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The mechanism(s) by which p53 chooses between 
outcomes of senescence or quiescence has remained 
elusive. A paper published in the recent issue of Cell 
Cycle indicates that this decision may be determined 
by p53 levels and their ability to selectively down-
regulate mTOR signaling. 
 
Activation of p53 plays a pivotal role in protecting 
against the survival and systemic spread of potential 
tumour cells. It can also influence the aging process 
and, reciprocally, p53 function has been reported to 
decline with age [1,2].  
 
The biological outcome of inducing p53 is of great 
topical interest, with much focus on the numerous 
factors that lead to growth arrest or programmed cell 
death (apoptosis). Until recently, however, less attention 
had been given to the mechanisms governing the choice 
between two distinct forms of growth arrest: 
quiescence, where cells enter a reversible non-cycling 
state, and senescence, an irreversible loss of 
proliferative potential that is coupled with specific 
changes in cell morphology and gene expression. 
However, fascinating insight into this issue has come 
from the work of Blagosklonny, Gudkov and 
colleagues, culminating in an article in Cell Cycle 
journal describing a role for increased p53 activity in 
favouring quiescence over senescence [3]. Significantly, 
while cellular senescence is of central relevance to the 
aging process, growing evidence that it may also be a 
key mechanism of tumour suppression [4] has generated 
much excitement over the last few years and 
underscores the importance of understanding its 
regulation. 
 
Recent studies from the Blagosklonny and Gudkov 
groups have shown that inducible ectopic expression of 
p21, a key p53 downstream target that is required for 
both senescence and  quiescence,  drives HT1080  fibro- 
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sarcoma cells into senescence [5]. Contrary to 
expectation, co-activation of p53 using the MDM2 
inhibitor Nutlin-3a suppresses the senescence mediated 
by p21 and makes the cells quiescent without altering 
the levels of p21. Notably, rapamycin, a classical 
inhibitor of the mTOR pathway, can also suppress p21-
mediated senescence suggesting the possibility that p53                     
might supress senescence by inhibiting mTOR 
signalling. Several key components of the mTOR 
pathway are, in fact, down-regulated by p53 [6] and, 
consistent with this idea, the Blagosklonny and Gudkov 
labs showed, in a subsequent publication [7], that 
silencing the expression of TSC2, an upstream inhibitor 
of mTORC1 that is induced by p53, partially changed 
Nutlin 3a-induced quiescence into senescence. In a 
reciprocal manner, cell lines that preferentially go into 
senesence upon Nultin-3a treatment are shunted back 
into quiescence if rapamycin is co-administered [7]. 
 
Having defined a model in which the choice between 
senescence or quiescence can depend upon mTOR 
signaling, the collaborating groups addressed an earlier 
observation that some p53 inducers, such as the DNA 
damaging agent doxorubicin, promote senescence while 
others, such as Nutlin 3a, lead to quiescence in the same 
cell type. Nutlin 3a works simply by uncoupling p53 
from its negative regulator MDM2. Doxorubicin, on the 
other hand, not only activates the DNA damage 
pathways but also promotes a series of phosphorylation 
and acetylation events in p53 that can fine tune p53 
function. So do these DNA damage-related events 
somehow interfere with suppression of senescence by 
p53 or is it the case that different levels of p53 
induction by the two different stimuli are responsible 
for the different outcomes? Working with immortalised 
human fibroblasts that undergo senescence upon 
treatment with doxorubicin, they now show [3] that low, 
but not high doses of this drug drive the cells into 
senescence. The finding that doxorubicin can bring 
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rules out the notion that the DNA damage pathways 
themselves mediate the switch. Moreover, the 
observation that suppression of doxorubicin-mediated 
senescence by Nutlin-3a is accompanied by super-
elevated p53 levels favours the model that p53 levels 
are the deciding factor. Also consistent with this model, 
Nutlin-3a itself, when given at low doses, favours a 
senescent phenotype although, curiously, this is only a 
partial effect. Collectively, these analyses pinpoint p53-
mediated inhibition of the mTOR pathway as a major 
effector in suppressing senescence, depending on 
whether p53 levels are above or below a critical 
threshold.  
 
These fascinating new findings also raise some new and 
pertinent questions. For example, how do different p53 
levels govern the senescence/quiescence switch? 
Presumably differential p53 sensitivity is likely to play 
a key role and analysis of the expression levels of the 
various mTOR target genes and their respective 
promoter activites may provide further evidence to 
support the model. Additionally, how does the mTOR 
pathway promote senescence mechanistically? What 
other pathways may influence the sense-
cence/quiescence choice and why does extended Nutlin-
3a treatment lead to senescence [3]? What are the 
implications for tumour suppression and for aging? And 
what lessons may be learned from the use of Nutlin-3a? 
This is a powerful inducer of p53 which, even at low 
levels, does not appear to bring about full commitment 
to senescence [3]. Perhaps, however, it lacks the 
subtlety, provided possibly by post-translational 
modifications or other stimulus-dependent events, that 
is so exquisitely essential to fine-tuning the p53 
response and governing its eventual biological outcome. 
Further investigation should provide some enlightening 
answers. 
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